Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity.
Sign Up to like & getrecommendations! Published in 2020 at "European journal of medicinal chemistry"
DOI: 10.1016/j.ejmech.2020.112186
Abstract: Anti-apoptotic protein BCL-XL plays a key role in tumorigenesis and cancer chemotherapy resistance, rendering it an attractive target for cancer treatment. However, BCL-XL inhibitors such as ABT-263 cannot be safely used in the clinic because… read more here.
Keywords: abt 263; protac; bcl degraders; target ... See more keywords